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Marc L. ReitmanTable 1. Adiposity and insulin resistance: Not always a simple correlation
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Adipocyte number up down or no down ? ? ?
Selected readingchange
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(2002). Diabetes 51, 624–630.
Note the difference from the usual correlation between adipose lipid content and insulin resistance and liver
Garg, A. (2004). N. Engl. J. Med. 350, 1220–lipid content in lipodystrophy, the fld mouse, and the adipose lipin mouse but not in the muscle lipin mouse.
1234.Data are from Phan and Reue (2005), Reitman (2002), and references therein.
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CAR: Three new models for a problem child
By comparison with its older and better-behaved cousins in the nuclear receptor superfamily, CAR (NR1I3) has always
been an oddball. Three new crystal structures recently described in Molecular Cell reveal the molecular basis for some of
its bad habits (Xu et al., 2004; Suino et al., 2004; Shan et al., 2004).CAR’s unruly behavior began with a diffi- p
cult birth. Its initial description (Baes et v
pal., 1994) was carefully considered and
rejected by three top journals skeptical w
vof its function as a constitutive tran-
scriptional activator, behavior that is t
now known to be common among or-6han receptors but was considered de- c
iiant at the time. And it really was an or-
han when it emerged first as MB67, s
1ith its original name (constitutive acti-
ator of retinoid response) a casualty of c
dhe peer review battle.
CAR (now constitutive androstane re- Aeptor) regained its birthright with the
dentification of its first ligands, andro-
tanol and androstenol (Forman et al.,
998). But conventional wisdom was
hallenged again, since these ligands
eactivated rather than activated CAR.
fter further struggles with more descrip-CELL METABOLISM : JANUARY 2005
P R E V I E Wtive alternatives, the journal insisted on
“inverse agonists,” a pharmacologic term
that has confused molecular biologists
ever since. (While conventional antago-
nists block the function of agonists, in-
verse agonists block basal activity of
their target.)
The first real clue to the physiologic
role of CAR came with the suggestion
that it was involved in the induction of
cytochrome P450 gene expression by a
series of drugs and foreign compounds
exemplified by phenobarbital (PB) (Hon-
kakoski et al., 1998). This was emphati-
cally borne out by the complete loss of
induction of drug metabolism in re-
sponse to appropriate xenobiotics in a
CAR knockout mouse (Wei et al., 2000).
CAR thus joined its closest relative PXR
as a “xenosensor.”
F
I
b
Drug metabolism is a central aspect a
of liver function with obvious and impor- b
ptant clinical implications. By inducing drug
oclearance pathways in response to a
e
very wide range of xenobiotics, CAR
and PXR generally function to protect us
from exogenous chemical threats. Sev-
eral recent studies suggest that CAR s
also controls metabolism of endobiotics, h
including bilirubin (Huang et al., 2003) a
and bile acids (Saini et al., 2004; Zhang h
et al., 2004), endogenous toxins, as well t
as key metabolic regulators such as thy-
o
roid hormone (Maglich et al., 2004; Qa-
C
tanani et al., 2004).
aThe chemical defense response con-
atrolled by CAR and PXR is reminiscent
bof the immune system in its ability to re-
cspond to a virtually unlimited number of
mforeign compounds. However, it is based
1on an essentially opposite strategy. Thus,
hboth receptors respond to a wide range
aof structurally diverse compounds rather
rthan to a unique hormone, and their cy-
ltochrome P450 targets and other down-
estream effectors have similarly extended
gsubstrate specificities. This iconoclastic
(behavior adds to the list of questions re-
wgarding the unusual functions of CAR.
aWhat is the molecular basis for constitu-
Itive transactivation? How do inverse ag-
ronists work? How does it respond to di-
verse xenobiotics?
cThe new structures provide a complex
wbut coherent answer to the question of
sconstitutive activity. In general, the ligand-
pdependent coactivator binding surface of
mthe nuclear receptors, termed AF-2, is
hdependent on appropriate positioning of
tthe C-terminal helix 12. Agonist ligands
often make direct contact with the inner aCELL METABOLISM : JANUARY 2005urface of this conformationally flexible t
elix to hold it in place and also stabilize a
ppropriate positions of other nearby t
elices. As expected, helix 12 adopts a
he active conformation in the structures
f human CAR bound to its agonists, t
ITCO and 5β-pregananedione, but folds p
cross a barrier of four internal amino c
cids rather than capping the ligand l
inding pocket (Xu et al., 2004). Two e
onserved features unique to CAR pro- r
ote the active conformation of helix p
2. The flexible loop that connects it to p
elix 10 in other receptors is replaced by m
short helix that holds it in place more r
igidly (Figure 1). At the other end, the p
ack of the usual C-terminal sequence a
xtension allows the terminal carboxyl u
roup to form a previously predicted i
Dussault et al., 2002) hydrogen bond q
ith a conserved lysine in helix 4 and c
lso with S337 from helix H10 (Figure 1). p
n essence, the helix is fastened to the r
est of the LBD like a staple. P
This model for the molecular basis of n
onstitutive activity contrasts strongly 2
ith others. In the Nurr1 structure, for in- a
tance, bulky side chains fill the ligand p
ocket and stabilize the active confor- t
ation (Wang et al., 2003). An extended r
elix 2 stabilizes the active LRH-1 struc-
ure, despite an empty pocket (Sablin et a
l., 2003). The new structures suggest figure 1. A schematic model depicting the active-to-inactive state transition of CAR
n the crystal structures of the active form of CAR, helix 12 of apo-CAR is stabilized in the active conformation
y the constraints of the short linker helix HX and hydrogen bonds (arrows) between the C-terminal carboxyl-
te and residues K205 from helix H4 and S337 from helix H10 (Xu et al., 2004; Suino et al., 2004). This allows
inding of coactivators via their conserved LXXLL motifs. Binding of the inverse agonist androstenol to CAR
romotes a collapse of the apo-pocket by introducing a kink of helix 10 at S337, which results in displacement
f the linker helix and AF-2 from the active configuration and dissociation of coactivator LXXLL motifs (Shan
t al., 2004) (E. Xu, personal communication).hat helix 2 reinforcement and possibly
lso the large surface of heterodimeriza-
ion with RXR may also stabilize the
ctive conformation of apo-CAR.
In contrast to the human structures,
he potent mouse CAR agonist TCPOBOP
okes through the barrier and directly
ontacts both helix 12 and the linker he-
ix (Suino et al., 2004). This presumably
xplains its ability to superactivate mu-
ine CAR in transfection studies. The
resence of the barrier also neatly ex-
lains the lack of such a response of hu-
an CAR to CITCO in similar studies but
aises the question of the basis for the
otent biologic effects of CITCO. The
nswer to this question lies in another
nique CAR activity. In the liver but not
n cultured cell lines, CAR is normally se-
uestered in the cytoplasm. It translo-
ates to the nucleus in response to a
oorly understood signal elicited by a
ange of secondary activators, including
B, bilirubin, and bile acids, which do
ot bind CAR (Swales and Negishi,
004). In such cases, the activation of
ppropriate target genes is clearly de-
endent on the constitutive activity, but
ranslocation can also be induced by di-
ect ligands like CITCO.
But if ligand binding is a dispensable
spect of CAR’s primary xenosensor
unction, why does it have a pocket at7
P R E V I E Wall? The structures of the TCPOBOP and a
aandrostanol bound murine CAR show
uthat the pocket allows not only translo-
2cation in response to specific xenobiotics
abut also more conventional allosteric mod-
tulation of CAR activity. Interestingly, the
mechanism of the inhibitory effects of
vthe inverse agonist differs from that of
ppreviously described nuclear receptor
aantagonists, which typically include a
lmoiety that projects into the space oc-
ccupied by helix 12 and actively disrupts
tthe AF-2 surface. By contrast, andros-
ttenol literally undermines the mechanisms
hthat promote the constitutive activity of
lCAR (Figure 1). In the androstenol bound
pstructure (Shan et al., 2004), the addi-
ytional helix that stabilizes helix 12 is dis-
Tplaced inward toward the ligand binding
acavity. This realigns the C-terminal helix
eand breaks the hydrogen bond that tacks
mit down to helix 4. Coactivators can no
tlonger bind, but corepressors may.
hThis mechanism is reminiscent of the
(“passive” antagonism in which THC
ibinding to ERβ subtly alters the confor-
mation of helix 10 (in the nomenclature
Dused for CAR) and thereby stabilizes an
Dinactive helix 12 conformation (Nettles et
al., 2004). Modulation of the positioning
B
of the C terminus of helix 10, which in-
1
cludes the dimer interface, has been H
suggested to be a key aspect of the allo-
steric effects of both ligand binding and S
dimerization (Nettles et al., 2004).
BWhile the new structures can explain
S
some of CAR’s odd habits, they also B
raise a number of questions. One of par-
D
ticular interest is the role of RXR. At least m
in the human CAR complexes, there is a (
direct contact between CAR helix 7 and F
the C terminus of RXR. This appears to S
Dbe dependent on the active conforma-
tion of RXR, which is unexpectedly pro- H
imoted by an adventitiously bound fatty8Hcid in the RXR ligand pocket. Predict-
Hbly, perhaps, RXR agonists can have
P
nusual effects on CAR (Tzameli et al.,
H003). Thus, the RXR partner may have
Cmore dynamic role than suggested by
he necessarily static crystal structures. M
wMore broadly, these structures pro-
Bide a firm foundation for design of new
harmacologic tools to modulate CAR N
Rctivity. CAR’s function in drug metabo-
eism suggests that such compounds
Could either promote the clearance of
Qoxic xenobiotics or prevent the forma-
Eion of toxic metabolites. However, if we
vave learned anything about CAR in the
Sast ten years, it is to expect the unex-
gected, and functions in processes be-
ond drug metabolism are emerging. S
hus, it has recently been suggested as H
atherapeutic target for jaundice (Huang
3t al., 2004). Based on its potential to
odulate thyroid hormone levels, inhibi- S
Lion of CAR has also been suggested to
Bave beneficial effects on weight loss
9Maglich et al., 2004). Who knows where
St will lead us next?
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